Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C28H52N5O5P |
Molecular Weight | 569.7167 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCCCCCCCCCCOCCCOP(O)(=O)CO[C@H](C)CN1C=NC2=C1N=CN=C2N
InChI
InChIKey=SCTJKHUUZLXJIP-RUZDIDTESA-N
InChI=1S/C28H52N5O5P/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-18-36-19-17-20-38-39(34,35)24-37-25(2)21-33-23-32-26-27(29)30-22-31-28(26)33/h22-23,25H,3-21,24H2,1-2H3,(H,34,35)(H2,29,30,31)/t25-/m1/s1
Molecular Formula | C28H52N5O5P |
Molecular Weight | 569.7167 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/8452366https://www.ncbi.nlm.nih.gov/pubmed/20439609Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/20439609 and http://ir.chimerix.com/releasedetail.cfm?releaseid=752310
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8452366https://www.ncbi.nlm.nih.gov/pubmed/20439609
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/20439609 and http://ir.chimerix.com/releasedetail.cfm?releaseid=752310
CMX157 is a lipid (1-0-hexadecyloxypropyl) conjugate of the acyclic nucleotide analog tenofovir (TFV) with activity against both wild-type and antiretroviral drug-resistant HIV strains, including multidrug nucleoside/nucleotide analog-resistant viruses. CMX157 was designed to mimic lysophosphatidylcholine to take advantage of natural lipid uptake pathways and to achieve high intracellular concentrations of the active antiviral, with the aim of increasing the effectiveness of TFV against wild-type and mutant HIV. CMX157 demonstrated potential to effectively suppress replication of multiNRTI-resistant (MNR) HIV that cannot be treated with any currently available NRTIs, including TDF. It is in phase II clinical trial for HIV infections in USA and phase Ib portion of the phase I/II trial for Hepatitis B in Thailand (PO).
CNS Activity
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8452366http://adisinsight.springer.com/drugs/800020504
Curator's Comment: reference retrieved from http://www.sciencedirect.com/science/article/pii/S2211383512001402
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL247 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9765248 |
58.0 µM [Kd] | ||
Target ID: HIV-1, subtype A 92RW009 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20439609 |
3.3 nM [EC50] | ||
Target ID: HIV-2 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20439609 |
3.5 nM [EC50] | ||
Target ID: HBV replication Sources: https://www.ncbi.nlm.nih.gov/pubmed/17646420 |
0.49 µM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | VIREAD Approved UseTenofovir disoproxil fumarate is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV and HBV infections Launch Date2012 |
|||
Primary | VIREAD Approved UseTenofovir disoproxil fumarate is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV and HBV infections Launch Date2012 |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: http://db.cbg-meb.nl/IB-teksten/h117062_fsuk.pdf
The recommended dose of Ictady (tenofovir disoproxil succinate) for the treatment of HIV or for the treatment of chronic hepatitis B is 245 mg (one tablet) once daily taken orally with food.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8452366
(R)-9-(2-Phosphonylmethoxypropyl)adenine (PMPA known as tenofovir) exerts antiretrovirus activity in MT-4 cells infected with HIV-1 and HIV-2 with EC50 values of 5.9 and 4.9 uM, respectively
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:44:16 GMT 2023
by
admin
on
Sat Dec 16 16:44:16 GMT 2023
|
Record UNII |
K7J545MEMA
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C97452
Created by
admin on Sat Dec 16 16:44:16 GMT 2023 , Edited by admin on Sat Dec 16 16:44:16 GMT 2023
|
||
|
NCI_THESAURUS |
C281
Created by
admin on Sat Dec 16 16:44:16 GMT 2023 , Edited by admin on Sat Dec 16 16:44:16 GMT 2023
|
||
|
FDA ORPHAN DRUG |
583917
Created by
admin on Sat Dec 16 16:44:16 GMT 2023 , Edited by admin on Sat Dec 16 16:44:16 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
10396
Created by
admin on Sat Dec 16 16:44:16 GMT 2023 , Edited by admin on Sat Dec 16 16:44:16 GMT 2023
|
PRIMARY | |||
|
K7J545MEMA
Created by
admin on Sat Dec 16 16:44:16 GMT 2023 , Edited by admin on Sat Dec 16 16:44:16 GMT 2023
|
PRIMARY | |||
|
23628250
Created by
admin on Sat Dec 16 16:44:16 GMT 2023 , Edited by admin on Sat Dec 16 16:44:16 GMT 2023
|
PRIMARY | |||
|
DB14925
Created by
admin on Sat Dec 16 16:44:16 GMT 2023 , Edited by admin on Sat Dec 16 16:44:16 GMT 2023
|
PRIMARY | |||
|
C152560
Created by
admin on Sat Dec 16 16:44:16 GMT 2023 , Edited by admin on Sat Dec 16 16:44:16 GMT 2023
|
PRIMARY | |||
|
100000174656
Created by
admin on Sat Dec 16 16:44:16 GMT 2023 , Edited by admin on Sat Dec 16 16:44:16 GMT 2023
|
PRIMARY | |||
|
911208-73-6
Created by
admin on Sat Dec 16 16:44:16 GMT 2023 , Edited by admin on Sat Dec 16 16:44:16 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PRODRUG |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|